Pimivalimab is under clinical development by Concentra Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pimivalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pimivalimab (JTX-4014) is under development for the treatment of solid tumors including non-small cell lung cancer. It is a fully human IgG4 monoclonal antibody. The drug candidate acts by targeting programmed death-1 (PD-1). It is administered through intravenous route.
Concentra Biosciences overview
Concentra Biosciences is a bioscience company that develops novel immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California, the US.
For a complete picture of Pimivalimab’s drug-specific PTSR and LoA scores, buy the report here.